MolMed S.p.A. (Milan:MLM) announces that the Company has filed to the European Medicines Agency an application for Conditional Marketing Authorisation for TK, its novel investigational cell-gene therapy. TK is an adjunctive treatment in hematopoietic stem cell transplantation (HSCT) for patients affected by high risk leukaemia. It is estimated that in EU approximately 5,000 leukaemia patients/year […]
MolMed Interim Financial Report 2013 Approved
The Board of Directors of MolMed S.p.A., chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2013. The most important elements were: TK: expansion in the US of the pivotal Phase III trial for high-risk leukaemia patients; NGR-TNF: continuation of the clinical development program; the increase of revenues […]
MolMed expands in the United States the Phase III trial of TK for the treatment of high-risk leukaemia
MolMed announces the enrolment of the first patient in the United States, initiating the cross-Atlantic expansion of the pivotal Phase III trial (TK008) of its proprietary TK cell/gene therapy for high-risk leukaemia patients. The study, already ongoing in Europe, foresees patient enrolment in 16 clinical centres worldwide. Claudio Bordignon, Chairman of the Board and CEO […]
MolMed, new data on NGR-hTNF: significant survival increase in sarcomas
MolMed, new data presented at the European Cancer Congress show a statistically significant increase in survival of patients suffering from soft tissue sarcomas treated with NGR-hTNF. MolMed S.p.A. (MLM.MI) presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO), in Amsterdam (The Netherlands), additional data from an ongoing randomized Phase II study evaluating safety […]
European Cancer Congress, MolMed on efficacy of drug NGR-hTNF
MolMed S.p.A. will present further data on the efficacy of the investigational drug NGR-hTNF in soft tissues sarcomas tomorrow at the European Cancer Congress. MolMed S.p.A. (MLM.MI) will present further data on the efficacy of its investigational drug NGR-hTNF in combination with doxorubicin in soft tissue sarcomas, tomorrow at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) taking […]
MolMed, Outcome of Shareholders’ meeting and meeting of Board of Directors
MolMed Shareholders’ Meeting confirms the appointment of a Member of the Board and approves Measures to be adopted pursuant to Article 2446 of the Italian Civil Code. Meeting of the Board of Directors: Professor Riccardo Cortese appointed as member of the Remuneration committee. Shareholders’ Meeting The Shareholders’ Meeting of MolMed S.p.A. (MLM.MI), chaired […]